Although its mechanism is not fully understood, we can reduce the iron intake of cancer cells through transferrin receptors, thus interfering with the iron metabolism of lung cancer cells and limiting their proliferation, thereby enabling novel therapy options for the treatment of lung cancer diseases. The gene discussed is TFRC; the disease is lung carcinoma.